GLPwatch
The prospective record-breaking obesity drug tirzepatide raises concerns about affordability.
J Basic Clin Physiol Pharmacol · 2023
Last updated 2026-05-28| Journal | J Basic Clin Physiol Pharmacol, 2023 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.20 |
| NIH percentile | 13 |
| Molecules | tirzepatide |
| Conditions studied | Obesity |
Full record and abstract on PubMed 37326670 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.